We propose rational designing of antiviral short-interfering RNA (siRNA) targeting highly divergent HIV-1. In this study, conserved regions within HIV-1 genomes were identified through an exhaustive computational analysis, and the functionality of siRNAs targeting the highest possible conserved regions was validated. We present several promising antiviral siRNA candidates that effectively inhibited multiple subtypes of HIV-1 by targeting the best conserved regions in pandemic HIV-1 group M strains.
Findings
RNA interference (RNAi) is now widely used to knockdown gene expression in a sequence-specific manner, making it a powerful tool not only for studying gene function, but also for therapeutic applications including antiviral treatments [1, 2] . The replication of a wide range of viruses can be successfully inhibited using RNAi with both short interfering RNA (siRNA) and siRNA expression vectors [3, 4] . However, for RNA viruses such as HIV-1, designing functional siRNAs that target viral sequences is problematic because of their extraordinarily high genetic diversity. We analyzed 495 entries of near full-length HIV-1 group M sequences available in the Los Alamos HIV Sequence Database, and selected the highest-possible conserved target sites for designing optimal antiviral siRNAs. It is known that RNAi-resistant viral mutants emerge rapidly when targeting viral sequences due to their high mutation rate [5] [6] [7] . Since highly conserved sequences are likely to contain structurally or functionally constrained elements, our approach is anticipated to resist viral mutational escape.
First, we performed a detailed analysis on the HIV-1 genome to identify highly conserved targets by using 495 near full-length genome sequences of HIV-1 group M (listed in Additional file 1). Every possible 21-mer was generated from all of the HIV-1 group M sequences, and their conservations among the 495 HIV-1 sequences were exhaustively determined using siVirus engine [8] . We defined 'conservation' as the percentage of sequence entries out of the 495 HIV-1 sequences that showed perfect identity (i.e., 21/21 matches) with the cognate 21-mer. Since many of the HIV-1 sequence entries lack 5' untranslated region (5' UTR), the 3' LTR sequence was used to compensate for the lack of 5' LTR sequences in order to avoid underestimating conservation in such regions. For the regions that cannot be compensated for in this way (depicted in Figure 1A However, our analysis has identified several distinct regions that are highly conserved in the HIV-1 genome ( Figure 1B ). Such regions include the regulatory domains responsible for the viral gene expression, such as the TATA sequence and polyadenylation signal (AAUAAA). In addition, several regions essential for the regulation of viral replication were also highly conserved, including the primer activation signal (PAS) [10] , primer binding site (PBS), packaging signal (Ψ), central polypurine tract (cPPT), central termination sequence (CTS), and 3' polypurine tract (3' PPT). All of these highly conserved sequences are constrained at the nucleotide sequence level or by their RNA secondary structure in order to execute their functions. In contrast, regions constrained by amino acid sequences were not necessarily conserved at the nucleotide sequence level due to the wobbling of the third base in the codon (data not shown). siRNAs targeting the highly conserved regions are expected to overwhelm the high level of sequence diversity of the HIV-1 genome, and also to reduce the chances of viral mutational escapes.
Total of 216 highly conserved (>70%) siRNA targets identified in this study are listed in Additional file 3. In mammalian RNAi, the efficacy of each siRNA varies markedly depending on its sequence. According to our guidelines for the selection of effective siRNAs [11, 12] , 31 out of 216 siRNAs were predicted to be functional. Similarly, 30 and 44 siRNAs are functional according to the algorithms reported by Reynolds et al. [13] , and Amarzguioui et al. [14] , respectively (Additional file 3). This suggests that only a limited fraction of 21-mers is best suited for use as functional antiviral siRNAs.
For the functional validation, 23 siRNAs from Additional file 3, and 18 additional siRNAs targeting moderatelyconserved regions were selected based on the following criteria: (I) predicted to be functional by the algorithm of Ui-Tei et al. [11, 12] , and (II) the sequence has perfect identity with pNL4-3 (GenBank M19921). The 41 siRNA sequences selected and their target sites are detailed in Additional file 4. We first tested the efficacy of each siRNA using target mRNA cleavage assay (Additional file 5 and [15] ). Briefly, a vector expressing reporter mRNA that contains the siRNA target site was cotransfected into HeLa cells with the corresponding siRNA, and the mRNA cleavage activity of the siRNA was evaluated by measuring the quantity of surviving mRNA using real-time RT-PCR. This assay allows us to directly monitor the sequence-dependent potency of siRNA itself, without being affected by the differences in target gene expression level or target secondary structures. The result showed that 39 out of the 41 siRNAs gave >60% silencing at 5 nM (Figure 2 , rightmost panel). si4794 and si4888 were not functional, probably due to the long consecutive Gs in si4794 and internal palindromes (AAAAUUUU) in si4888 [11, 13] . . si689 and si690 did not inhibit viral replication even though these siRNAs perfectly matched to their target sites (confirmed by DNA sequencing of the infectious molecular clones). This is probably due to the stable secondary structure at the si689-690 target sites in both BMH (branched multiple hairpin) conformation and LDI (long distance interaction) conformation of the HIV-1 leader RNA [18] (see Additional file 4). It should be noted that the efficacy of si575 differed when targeting pNL4-3 and 93IN101. One possible explanation for this is the secondary structure differences among HIV-1 subtypes, which may alter the accessibility of the si575 target site.
The approach described here enabled us to select highly effective siRNAs against divergent HIV-1 strains at a high rate. The highly effective siRNAs (>90% inhibition) with maximal conservation (>70%) identified in our study include si521 (poly A site; 94% conservation), si764/770 (Ψ; 88%), si510 (TAR/poly A; 84%), si2075 (ribosomal slip site; 70%), si2329/2330/2333 (protease region; 77%), and si4750/4751/4753 (integrase region; 71-74%). These sites are found mostly in the 5' LTR, protease, and integrase regions (Figure 2 ). However, the extraordinarily high genetic diversity of HIV-1 obviously prevents us from designing a single siRNA that can nullify all HIV-1 strains currently circulating worldwide (Additional file 7). One possible approach is to combine multiple siRNAs targeting different conserved regions [19, 20] . The siRNAs selected and validated in this study have the potential to target >99% of HIV-1 strains by combining only two siRNAs (Additional file 7), and also considered to resist viral mutational escape. Our approach is expected to be highly applicable to therapeutic intervention for other pathogens of public health importance, including HCV, influenza virus, and SARS coronavirus, that are known to show high genetic diversity.
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